Exosomes and the secretome.

The companion primer on what a mesenchymal stem cell is ends on a pivotal point: these cells appear to work primarily by secreting signals rather than by turning into replacement tissue. If that is true, then the therapeutic agent is not really the cell itself — it is the collection of molecules the cell puts out. Researchers call that collection the secretome.

The secretome is a rich, dynamic mixture: soluble growth factors, cytokines and chemokines, and — importantly — membrane-bound packages called extracellular vesicles. It is not a fixed recipe. Cells tune what they release in response to the environment they find themselves in, which is exactly why an MSC dropped into inflamed tissue behaves differently from one sitting in a calm culture dish.

The core idea

If the benefit lives in the secretome, then in principle you could purify the active fraction and deliver it without the living cell — so-called cell-free therapy. Exosomes are the most talked-about candidate for that active fraction.

An exosome is a tiny membrane-bound vesicle — roughly 30 to 150 nanometres across, hundreds of times smaller than the cell that made it — released by nearly every cell type in the body. Far from being cellular debris, exosomes are a genuine communication system: cells use them to shuttle molecular cargo to other cells, near and far.^[1]

The cargo is the interesting part. Inside and on the surface of an exosome you find proteins, lipids, and — critically — nucleic acids, especially microRNAs: short regulatory RNA molecules that can change which genes a recipient cell switches on or off. When a target cell takes up an exosome, it effectively receives a package of instructions. This is how one cell reprograms the behavior of another without any direct contact.^[2]

Terminology note, because the marketing often blurs it: "exosome" is a specific subtype of the broader category extracellular vesicles (EVs). Because purification methods rarely isolate one subtype cleanly, careful scientists increasingly say "small extracellular vesicles." Many products sold as "exosomes" are, more accurately, mixed EV preparations. The distinction matters when you are evaluating a claim.

The appeal of a cell-free therapy is not hard to see. A living-cell product is logistically demanding: the cells must be kept viable, delivered on a timeline, and — being alive — carry at least a theoretical concern about how they behave once inside the body. A purified vesicle preparation sidesteps much of that. It behaves more like a conventional biologic drug: it can be characterized, potentially stored, and dosed with more consistency.^[3]

The promise is real. So is the gap between a promising mechanism and a proven, standardized therapy — and that gap is where a patient should focus attention.

There is also a scientific elegance to it. If the exosome carries the same regenerative and immunomodulatory microRNA cargo that gives MSCs their effect, then it may reproduce much of the benefit while stripping away the complexity of the cell. That is a compelling hypothesis. It is, at this stage, still substantially a hypothesis in humans.

In the laboratory and in animal models, MSC-derived exosomes have shown genuinely encouraging results across a range of injury models — cardiac, kidney, neurological, and wound-healing among them. One of the earliest and most-cited demonstrations showed that vesicles secreted by MSCs reduced tissue damage in a model of heart injury, reproducing a key effect of the cells themselves.^[4] A large preclinical literature has since built on that finding.

The honest picture in humans is far earlier. Rigorous, controlled human trials of exosome therapy remain limited, and the field faces a hard, unglamorous obstacle: standardization. There is not yet broad agreement on how to isolate, quantify, characterize, and dose exosome products, which makes it difficult to compare studies or guarantee that two vials labeled the same actually contain the same thing.^[5] The International Society for Extracellular Vesicles has published guidance (the "MISEV" standards) precisely because the field needed a common yardstick.^[5]

This is not a reason for cynicism — it is the normal, necessary middle stage of a technology that may well mature into something important. It is a reason for precision about what is established and what is aspirational.

Exosomes are, at the moment, one of the most aggressively marketed products in regenerative medicine — and that is exactly the context in which a patient should be most careful. Regulators have taken notice. In the United States, the FDA has issued public warnings about unapproved exosome products, following adverse events linked to unregulated preparations.^[6] No exosome product is FDA-approved as a treatment for the conditions it is commonly marketed for.

Where does that leave the technology? Genuinely promising, mechanistically coherent, and still in the process of proving itself in people. It sits at the frontier of the same paracrine logic that already underpins cell therapy — a logical next chapter, not a finished one. A clinic worth trusting will describe it in exactly those terms rather than as a settled cure, and will not let enthusiasm outrun the evidence.

For the established side of this story — the cells whose signaling started the whole inquiry — see the primers on mesenchymal stem cells and where those cells come from.